Supplementary Figure S14. *In vivo* efficacy of ABT-263 in combination with established drugs against ALL-2, ALL-19 and ALL-31. ABT-263 was combined with (A) vincristine (VCR), (B) dexamethasone (DEX) or (C) L-asparaginase (L-ASN). Left panels for each xenograft, %huCD45+ of individual mice over time; right panels for each xenograft, proportion of mice remaining event-free. Shaded areas indicate the treatment period.

**A** ABT-263 + VCR

**B** ABT-263 + DEX

**C** ABT-263 + L-ASN
Supplementary Figure S15. MCL1 protein expression at different stages of spleen extraction. Proteins were extracted as described in the Materials and Method from two spleens at three stages: (1) freshly harvested spleen and post red cell lysis, (2) splenocytes post-Ficoll separation and (2) splenocytes post-Ficoll separation and cryopreservation. HL-60 and Raji cells were included as controls.